sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_7 ;
    pav:version "20131211" .
  sub:_6 prov:value "TNF? also induced in HUVEC, a marked time- and dose-dependent stimulation of SAPK2/p38 that is characterized by an increased activity of MAPKAP K2/3, a direct physiological target of SAPK2/p38 (21). Maximal stimulation was obtained after a 10-min exposure to concentrations of TNFalpha equal to or higher than 5 ng/ml (Fig. 3,A and B). The pyridinylimidazole derivative SB203580, in concentrations of 1?5 ?m, completely inhibited the TNFalpha-induced increase in SAPK2/p38 activity as reflected by the inhibition of MAPKAP K2/3 activation in cells exposed to TNFalpha (Fig. 3  C). " ;
    prov:wasQuotedFrom pubmed:11448946 .
  sub:_7 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:11448946 ;
    prov:wasDerivedFrom beldoc: , sub:_6 .
}